Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort

J. W. Hiemenz, I. I. Raad, J. A. Maertens, R. Y. Hachem, A. J. Saah, C. A. Sable, J. A. Chodakewitz, M. E. Severino, P. Saddier, R. S. Berman, D. M. Ryan, M. J. Dinubile, Thomas F Patterson, D. W. Denning, T. J. Walsh

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

In a non-comparative study, caspofungin was effective salvage therapy for approximately half of the patients refractory to or intolerant of standard antifungal agents for invasive aspergillosis. To establish a frame of reference for these results, we compared the response to caspofungin with responses to other antifungal agents in a historical cohort of similar patients. The efficacy could be evaluated in 83 patients who received caspofungin 50 mg daily after a 70-mg loading dose. The historical control group, identified through a retrospective review of medical records, included 214 evaluable patients possibly refractory to or intolerant of ≥1 week of standard antifungal therapy. All patients had documented invasive aspergillosis. Favorable response was defined as a complete or partial response to therapy. Underlying diseases, baseline neutropenia, corticosteroid use, and sites of infection were similar in both studies. Most patients had received amphotericin B formulations and/or itraconazole, and were refractory to standard therapy. Favorable response rates were 45% with caspofungin and 16% with standard therapy. The unadjusted odds ratio for a favorable response (caspofungin/standard therapy) was 4.1 (95% confidence interval: 2.2, 7.5). After adjusting for potential imbalances in the frequency of disseminated infection, neutropenia, steroid use, and bone marrow transplantation between groups, the odds ratio remained at 4.1 (2.1, 7.9). Although only tentative conclusions about relative efficacy can be drawn from retrospective comparisons, caspofungin appeared to be at least as efficacious as an amphotericin B formulation and/or itraconazole for the treatment of invasive aspergillosis in patients refractory to or intolerant of their initial antifungal therapy.

Original languageEnglish (US)
Pages (from-to)1387-1394
Number of pages8
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Volume29
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

caspofungin
Salvage Therapy
Aspergillosis
Itraconazole
Antifungal Agents
Amphotericin B
Neutropenia
Therapeutics
Odds Ratio
Infection
Bone Marrow Transplantation
Medical Records
Adrenal Cortex Hormones
Steroids

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. / Hiemenz, J. W.; Raad, I. I.; Maertens, J. A.; Hachem, R. Y.; Saah, A. J.; Sable, C. A.; Chodakewitz, J. A.; Severino, M. E.; Saddier, P.; Berman, R. S.; Ryan, D. M.; Dinubile, M. J.; Patterson, Thomas F; Denning, D. W.; Walsh, T. J.

In: European Journal of Clinical Microbiology and Infectious Diseases, Vol. 29, No. 11, 11.2010, p. 1387-1394.

Research output: Contribution to journalArticle

Hiemenz, JW, Raad, II, Maertens, JA, Hachem, RY, Saah, AJ, Sable, CA, Chodakewitz, JA, Severino, ME, Saddier, P, Berman, RS, Ryan, DM, Dinubile, MJ, Patterson, TF, Denning, DW & Walsh, TJ 2010, 'Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort', European Journal of Clinical Microbiology and Infectious Diseases, vol. 29, no. 11, pp. 1387-1394. https://doi.org/10.1007/s10096-010-1013-0
Hiemenz, J. W. ; Raad, I. I. ; Maertens, J. A. ; Hachem, R. Y. ; Saah, A. J. ; Sable, C. A. ; Chodakewitz, J. A. ; Severino, M. E. ; Saddier, P. ; Berman, R. S. ; Ryan, D. M. ; Dinubile, M. J. ; Patterson, Thomas F ; Denning, D. W. ; Walsh, T. J. / Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. In: European Journal of Clinical Microbiology and Infectious Diseases. 2010 ; Vol. 29, No. 11. pp. 1387-1394.
@article{7b0837039ed14ea4ba5f19a28ed157fd,
title = "Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort",
abstract = "In a non-comparative study, caspofungin was effective salvage therapy for approximately half of the patients refractory to or intolerant of standard antifungal agents for invasive aspergillosis. To establish a frame of reference for these results, we compared the response to caspofungin with responses to other antifungal agents in a historical cohort of similar patients. The efficacy could be evaluated in 83 patients who received caspofungin 50 mg daily after a 70-mg loading dose. The historical control group, identified through a retrospective review of medical records, included 214 evaluable patients possibly refractory to or intolerant of ≥1 week of standard antifungal therapy. All patients had documented invasive aspergillosis. Favorable response was defined as a complete or partial response to therapy. Underlying diseases, baseline neutropenia, corticosteroid use, and sites of infection were similar in both studies. Most patients had received amphotericin B formulations and/or itraconazole, and were refractory to standard therapy. Favorable response rates were 45{\%} with caspofungin and 16{\%} with standard therapy. The unadjusted odds ratio for a favorable response (caspofungin/standard therapy) was 4.1 (95{\%} confidence interval: 2.2, 7.5). After adjusting for potential imbalances in the frequency of disseminated infection, neutropenia, steroid use, and bone marrow transplantation between groups, the odds ratio remained at 4.1 (2.1, 7.9). Although only tentative conclusions about relative efficacy can be drawn from retrospective comparisons, caspofungin appeared to be at least as efficacious as an amphotericin B formulation and/or itraconazole for the treatment of invasive aspergillosis in patients refractory to or intolerant of their initial antifungal therapy.",
author = "Hiemenz, {J. W.} and Raad, {I. I.} and Maertens, {J. A.} and Hachem, {R. Y.} and Saah, {A. J.} and Sable, {C. A.} and Chodakewitz, {J. A.} and Severino, {M. E.} and P. Saddier and Berman, {R. S.} and Ryan, {D. M.} and Dinubile, {M. J.} and Patterson, {Thomas F} and Denning, {D. W.} and Walsh, {T. J.}",
year = "2010",
month = "11",
doi = "10.1007/s10096-010-1013-0",
language = "English (US)",
volume = "29",
pages = "1387--1394",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Vieweg",
number = "11",

}

TY - JOUR

T1 - Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort

AU - Hiemenz, J. W.

AU - Raad, I. I.

AU - Maertens, J. A.

AU - Hachem, R. Y.

AU - Saah, A. J.

AU - Sable, C. A.

AU - Chodakewitz, J. A.

AU - Severino, M. E.

AU - Saddier, P.

AU - Berman, R. S.

AU - Ryan, D. M.

AU - Dinubile, M. J.

AU - Patterson, Thomas F

AU - Denning, D. W.

AU - Walsh, T. J.

PY - 2010/11

Y1 - 2010/11

N2 - In a non-comparative study, caspofungin was effective salvage therapy for approximately half of the patients refractory to or intolerant of standard antifungal agents for invasive aspergillosis. To establish a frame of reference for these results, we compared the response to caspofungin with responses to other antifungal agents in a historical cohort of similar patients. The efficacy could be evaluated in 83 patients who received caspofungin 50 mg daily after a 70-mg loading dose. The historical control group, identified through a retrospective review of medical records, included 214 evaluable patients possibly refractory to or intolerant of ≥1 week of standard antifungal therapy. All patients had documented invasive aspergillosis. Favorable response was defined as a complete or partial response to therapy. Underlying diseases, baseline neutropenia, corticosteroid use, and sites of infection were similar in both studies. Most patients had received amphotericin B formulations and/or itraconazole, and were refractory to standard therapy. Favorable response rates were 45% with caspofungin and 16% with standard therapy. The unadjusted odds ratio for a favorable response (caspofungin/standard therapy) was 4.1 (95% confidence interval: 2.2, 7.5). After adjusting for potential imbalances in the frequency of disseminated infection, neutropenia, steroid use, and bone marrow transplantation between groups, the odds ratio remained at 4.1 (2.1, 7.9). Although only tentative conclusions about relative efficacy can be drawn from retrospective comparisons, caspofungin appeared to be at least as efficacious as an amphotericin B formulation and/or itraconazole for the treatment of invasive aspergillosis in patients refractory to or intolerant of their initial antifungal therapy.

AB - In a non-comparative study, caspofungin was effective salvage therapy for approximately half of the patients refractory to or intolerant of standard antifungal agents for invasive aspergillosis. To establish a frame of reference for these results, we compared the response to caspofungin with responses to other antifungal agents in a historical cohort of similar patients. The efficacy could be evaluated in 83 patients who received caspofungin 50 mg daily after a 70-mg loading dose. The historical control group, identified through a retrospective review of medical records, included 214 evaluable patients possibly refractory to or intolerant of ≥1 week of standard antifungal therapy. All patients had documented invasive aspergillosis. Favorable response was defined as a complete or partial response to therapy. Underlying diseases, baseline neutropenia, corticosteroid use, and sites of infection were similar in both studies. Most patients had received amphotericin B formulations and/or itraconazole, and were refractory to standard therapy. Favorable response rates were 45% with caspofungin and 16% with standard therapy. The unadjusted odds ratio for a favorable response (caspofungin/standard therapy) was 4.1 (95% confidence interval: 2.2, 7.5). After adjusting for potential imbalances in the frequency of disseminated infection, neutropenia, steroid use, and bone marrow transplantation between groups, the odds ratio remained at 4.1 (2.1, 7.9). Although only tentative conclusions about relative efficacy can be drawn from retrospective comparisons, caspofungin appeared to be at least as efficacious as an amphotericin B formulation and/or itraconazole for the treatment of invasive aspergillosis in patients refractory to or intolerant of their initial antifungal therapy.

UR - http://www.scopus.com/inward/record.url?scp=78449250756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78449250756&partnerID=8YFLogxK

U2 - 10.1007/s10096-010-1013-0

DO - 10.1007/s10096-010-1013-0

M3 - Article

VL - 29

SP - 1387

EP - 1394

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

IS - 11

ER -